Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Bortezomib + Cyclophosphamide + Daratumumab + Hyaluronidase-fihji + Dexamethasone is FDA approved for newly diagnosed AL Amyloidosis/Light Chain Amyloidosis. Approval date: January 15, 2021, based on the ANDROMEDA trial.
Bortezomib + Cyclophosphamide + Daratumumab + Hyaluronidase-fihji + Dexamethasone is EMA approved for adult patients with newly diagnosed systemic light chain (AL) amyloidosis. Evidence is based on a study with 388 patients.
see also:
[AL Amyloidosis/Light Chain Amyloidosis …